NextPlat Q3 2026 net loss narrows 66% to $748,000
NXPL•NextPlat’s third-quarter 2026 net loss attributable to common stockholders narrowed 66% year over year to $748,000, while revenue fell 24% to $10.5 million. Gross margin was 35%, and pharmacy contract revenue quadrupled to approximately $2.4 million.
1. Quarter results
NextPlat’s third-quarter 2026 net loss attributable to common stockholders narrowed 66% year over year to $748,000. Revenue fell 24% to $10.5 million, reflecting lower healthcare reimbursement rates and retail prescription volumes, while gross margin reached 35%.
2. Pharmacy growth plans
Pharmacy contract revenue quadrupled year over year to approximately $2.4 million. A nationwide medication fulfillment website remains scheduled to launch in the fourth quarter, expanding PharmcoRx’s reach beyond Florida.
